Mark Mattson

Mark Mattson led the Laboratory of Neurosciences at the National Institute on Aging, part of the National Institutes of Health, for many years before continuing his research as a professor in the Department of Neuroscience at Johns Hopkins University School of Medicine [2]. His research program has focused on the cellular and molecular effects of intermittent fasting and caloric restriction on the brain, particularly on mechanisms relevant to aging and neurodegenerative disease [1].

In a widely cited 2018 review, "Intermittent metabolic switching, neuroplasticity and brain health," Mattson and colleagues laid out the core mechanistic argument behind intermittent fasting's neurological effects: cycling between a fed, glucose-burning metabolic state and a fasted state that shifts toward ketone-body metabolism triggers what the paper calls "intermittent metabolic switching," which upregulates brain-derived neurotrophic factor (BDNF), a protein central to neuron growth and synaptic plasticity, and activates autophagy, the cell's process for clearing damaged proteins and organelles [1]. The same review cites animal studies in which various intermittent fasting regimens extended lifespan by up to 40% relative to unrestricted feeding, and separately discusses parallels between fasting-induced signaling and the pathways targeted by rapamycin, situating intermittent fasting within the same broader mTOR-related mechanistic territory studied by researchers like Linda Partridge and Matt Kaeberlein [1].

Mattson's own public health message, drawn from this body of work, has generally emphasized the specific ketone body beta-hydroxybutyrate (BHB) as a signaling molecule with effects beyond simple fuel provision, arguing it can directly influence gene expression relevant to stress resistance and neuroprotection [1]. He has also been careful in his academic writing to distinguish between fasting effects demonstrated in animal models, primarily rodents, and the comparatively sparser and more preliminary human trial evidence, a distinction that is frequently lost when this research is summarized for a general audience in shorter-form health media [1].

A National Institute on Aging symposium held in Mattson's honor recognized him as what NIA itself described as a pioneering figure connecting neuroscience and fasting research, reflecting his standing within the federal aging-research establishment specifically, rather than only within the more commercially oriented longevity media space where intermittent fasting claims are frequently amplified beyond what the underlying animal and early human data support.

Mattson does not appear in available reporting to hold founder equity in a commercial intermittent-fasting app, supplement, or program comparable to Valter Longo's L-Nutra; his career output has been overwhelmingly academic and government-research based rather than commercial, which is a meaningfully different financial position than several other researchers profiled in this reference whose personal income is more directly tied to selling a specific fasting or dietary product.

The plain takeaway: Mattson's mechanistic work on BDNF, ketone signaling, and autophagy in the context of intermittent fasting is genuinely foundational to the modern scientific case for fasting's brain-health effects, and it comes from a career built inside NIH and academic institutions rather than a fasting-product company, but the review literature he himself authored is explicit that the strongest lifespan-extension results remain in animal models, with human evidence still comparatively limited.